|
|
|
|
|
|
Sponsored by: |
University Hospital Birmingham |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00553566 |
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
PURPOSE: This clinical trial is studying how dietary, lifestyle, and environmental factors affect patients with early-stage bladder cancer.
Condition | Intervention | Phase |
Bladder Cancer |
Procedure: medical chart review Procedure: questionnaire administration Procedure: study of socioeconomic and demographic variables |
Phase III |
Genetics Home Reference related topics: | bladder cancer |
MedlinePlus related topics: | Bladder Cancer Cancer |
Study Type: | Observational |
Official Title: | Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [COHORT] |
Estimated Enrollment: | 1600 |
Study Start Date: | December 2005 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Detailed information will be collected about the patients' lifestyle and their exposure to risk factors associated with bladder cancer using semi-structured questionnaires. A baseline questionnaire will be administered at the time of diagnosis and will collect information about socio-demographics, environmental exposures, medical history, diet, health-related quality of life, and social support.
Further questionnaires will be administered at regular follow-up visits to capture information relating to changes in exposure. A postal questionnaire will be used to collect historical information that may require the patient to check records or consult family or friends. Patients will also be asked to keep a 1-week food, fluid, and micturition diary.
Patients continue to complete questionnaires at 3 months and then annually for up to 5 years.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically proven urothelial cancer meeting one of the following criteria:
Exclusion criteria:
PATIENT CHARACTERISTICS:
Inclusion criteria:
Exclusion criteria:
PRIOR CONCURRENT THERAPY:
United Kingdom, England | |||||
Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust | Recruiting | ||||
Birmingham, England, United Kingdom, B15 2TH | |||||
Contact: K. K. Cheng, MD 44-121-414-6757 |
University Hospital Birmingham |
Study Chair: | K. K. Cheng, MD | University Hospital Birmingham |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000574078, CRUK-BCPP-2005-01-COHORT, ISRCTN13889738, EU-20768 |
First Received: | November 2, 2007 |
Last Updated: | November 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00553566 |
Health Authority: | Unspecified |
|
|
|
|